Metagenomi Aims for Q4 2026 IND Filing with $140M Cash Runway
Metagenomi expects to file an IND for its MGX-001 hemophilia A program in Q4 2026, aiming for first-in-human studies in 2027, and has recruited Dr. Kapil Saxena to lead clinical development. As of March 31, 2026, the company held $140.2 million in cash and equivalents, funding operations through Q4 2027.
1. MGX-001 Development Progress
Metagenomi’s lead MGX-001 program for hemophilia A remains on track for regulatory submission in Q4 2026, with first-in-human trials slated for 2027. The company bolstered its clinical team by hiring Dr. Kapil Saxena to oversee the IND-enabling and trial initiation activities.
2. Platform Technology Update
A recent publication in Nature Structural & Molecular Biology detailed MG119-28, a proprietary compact CRISPR nuclease demonstrating superior genome editing efficiency compared with other Cas12f-class enzymes, underscoring Metagenomi’s platform strength.
3. Financial Position and Expenses
As of March 31, 2026, Metagenomi held $140.2 million in cash, cash equivalents, and marketable securities, projected to support operations through Q4 2027. R&D expenses fell to $19.3 million from $25.1 million year-over-year, while G&A costs dipped to $6.5 million from $6.8 million.